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a b s t r a c t
Aims: Fetuin-A, a protein exclusively secreted from the liver, is associated with insulin
resistance and/or metabolic syndrome (MetS). However, few studies have examined this
association in Japan. We investigated this issue in a Japanese general population.
Methods: We performed an epidemiological survey in a small community in Japan. The
participants consisted of 659 subjects (253 males and 406 females). Fetuin-A levels were
measured by a sandwich ELISA method and the modified NCEP-ATP III criteria were adopted
to diagnose MetS. The homeostasis model assessment index (HOMA-IR) was calculated as a
marker of insulin resistance.
Results: Statistically significant characteristics of the 659 subjects stratified by fetuin-A
quartiles were male gender (inversely), age (inversely), insulin, HOMA-IR, uric acid (inverse-
ly), alcohol intake (inversely) and the prevalence of MetS. Mean fetuin-A levels were
249.7  45.1 mg/ml in males and 262.7  55.8 mg/ml in females. In males, the prevalence
of MetS was 43.1%, and their mean HOMA-IR level was 1.1. In females, the prevalence of
MetS was 17.7%, and their mean HOMA-IR level was 0.9. Multiple stepwise regression
analyses showed that fetuin-A levels in males but not females were independently associ-
ated with MetS and LDL-c. Multiple logistic regression analysis of fetuin-A (quartile 1 vs.
quartile 4) in males showed significant odds ratios of 1.009 (95% C.I.: 1.003–1.015) for MetS
and 1.376 (95% C.I.: 1.027–1.844) for 1-SD increment increase in LDL-c.
Conclusions: High plasma fetuin-A levels were associated with MetS in community-dwelling
Japanese males but not females.
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distributions in both genders.1. Introduction
Fetuin-A (alpha-2-Heremans-Schmid glycoprotein: AHSG) is a
liver-synthesized protein that is secreted into serum and is a
potent circulating inhibitor of the precipitation of calcium and
phosphorus [1–3]. In animal studies, fetuin-A is a multifunc-
tional molecule and acts as an antagonist of transforming
growth factor b and cytokine-dependent osteogenesis [4,5].
Moreover, fetuin-A binds directly the extracellular domain of
the insulin receptor and inhibits insulin receptor tyrosine
kinase activity [5]. In animals, fetuin-A knockout mice are
insulin-sensitive and resistant to weight gain [3,5]. Conversely,
injection of fetuin-A into mice induces insulin-resistance [6].
In humans, high circulating fetuin-A levels have been
linked to the metabolic syndrome (MetS) including obesity,
fatty liver disease, atherogenic dyslipidemia and insulin
resistance as hallmarks of MetS [7,8]. Reports from different
populations (Caucasians vs. Asians [7–14], males vs. females
[11,15], obese vs. non-obese subjects [13,14,16,17],
non-diabetics vs. diabetics [18–20], young vs. old persons
[18,20–23], and patients with cardiovascular diseases vs.
general populations [24–27]) indicated that plasma fetuin-A
is associated with insulin resistance or MetS and is an
independent risk factor of type 2 diabetes [13,15,17–22].
However, there is little information available for this associa-
tion in Japan. We investigated this issue in a Japanese general
population.
2. Materials and methods
2.1. Study population
A total of 673 subjects (260 males and 413 females) aged over 40
years received a population-based health examination in a
fishing community in southwestern Japan, Uku town, from
2009 to 2012. This town is an isolated island in Sasebo city,
located in Nagasaki prefecture, and the total population is
about 3700. Of these, we excluded 14 subjects whose fetuin-A
data were missing or who rejected the blood tests. Conse-
quently, 659 subjects (253 males and 406 females) were
enrolled in this study.
2.2. Data collection
Height and weight were measured, and body mass index (BMI)
was calculated as weight (kilograms) divided by the square of
height (square meters) as an index of the presence or absence
of obesity. Waist circumference was measured at the level of
the umbilicus in a standing position. Blood pressure (BP) was
measured twice with the subjects in the sitting (first) and
supine (second) position. Vigorous physical activity and
smoking were avoided for at least 30 min before BP measure-
ments. The second BP with the fifth phase diastolic pressure
was used for analysis.
Hypertensives were defined as those with BP  140/
90 mmHg and/or those receiving antihypertensive medication.
Blood was drawn from the antecubital vein for determina-
tions of lipids profiles (total cholesterol, high-density lipoproteincholesterol [HDL-c], low-density lipoprotein cholesterol [LDL-c]
and triglycerides), creatinine, uric acid (UA), fasting plasma
glucose (FPG), insulin, glycated hemoglobin A1c [HbA1c(NGSP)/
mmol/mol (IFCC)], liver enzymes [alanine aminotransferase
(ALT), aspartate aminotransferase  (AST), and g-glutamyl trans-
peptidase (g-GTP)], gender hormones (estradiol, testosterone
and progesterone) and plasma fetuin-A levels in the morning
after a 12-h fast. Fasting blood samples were centrifuged within
1 h after the collection. Estimated glomerular filtration rate
(eGFR) was calculated using the modification of diet in renal
disease (MDRD) study equation modified with a Japanese
coefficient [28]. Fetuin-A levels were measured by a sandwich
ELISA method (BioVendor Laboratory Medicine, Brno, Czech
Republic) [7]. Intra- and inter-assay coefficients of variation of
fetuin-A at a commercially available laboratory (SRL Inc.
Fukuoka, Japan) were 5.2% and 3.8%, respectively.
The homeostasis model assessment index (HOMA-IR) was
calculated from FPG and insulin levels [FPG (mg/dl)  insulin
(mU/ml)/405] as a marker of insulin resistance [29]. Subjects
with type 2 diabetes mellitus were defined as those with
FPG  126 mg/dl or HbA1c  6.5%, or those taking oral hypo-
glycemic agents and/or receiving insulin injection. Subjects
with dyslipidemia were defined as those with LDL-c  140 mg/
dl and/or triglycerides 150 mg/dl and/or HDL-c < 40 mg/dl
and/or those taking lipid-lowering drugs.
We defined the metabolic syndrome according to ATP III
(Adult Treatment Panel III) [30]. ATP III identified 5 compo-
nents of the metabolic syndrome [abdominal obesity; given as
waist circumference (>101.6 cm for males, >88.9 cm for
females)], triglycerides (150 mg/dl), HDL-c (<40 mg/dl for
males, <50 mg/dl for females), blood pressure (130 and/or
85 mmHg) and FPG (110 mg/dl). However, Japanese are
much smaller than people of western countries, therefore, it is
not appropriate to use the criteria of abdominal obesity of ATP
III. Accordingly, we adopted 85 cm for males and 90 cm for
females of waist circumference, proposed by the Japanese
Society for Obesity [31]. When three of the five listed criteria
were met, a subject was diagnosed as having MetS.
The average consumption of alcohol was categorized into
four groups [non (0 g), light (<23 g), moderate (23–45 g) and
heavy (46 g)] [32].
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department of Uku town, as well as by the ethics committee of
Kurume University. All participants gave informed consent.
2.3. Statistical analysis
Because of skewed distributions, natural logarithmic (ln)
transformations were performed for triglycerides, insulin,
HOMA-IR, estradiol, testosterone, and progesterone. Log-
transformed values were reconverted to antilogarithm forms
in the tables. The medications for hypertension, dyslipidemia
and diabetes mellitus were coded as dummy variables. Gender,
smoking habits and MetS were also coded as dummy variables.
First, mean fetuin-A level was classified into quartiles. Second,
we performed univariate analysis with fetuin-A as a dependentTable 1 – Characteristics of study subjects in fetuin-A quartile
Characteristics Quartile 1 Quartile 2
Number 163 163 
Male % (n:yes) 44.2 (72) 43.6 (71) 
Fetuin-A (mg/ml) 190.7  25.4 242.6  9.9 
Age (years) 66.7  9.2 67.2  9.5 
BMI (kg/m2) 23.4  3.1 23.7  3.5 
Waist (cm) 82.4  8.9 83.2  10.2 
Systolic BP (mmHg) 135.6  17.5 135.7  19.1
Diastolic BP (mmHg) 81.1  9.5 81.6  10.0 
FPG (mg/dl) 96.8  16.9 96.2  18.2 
HbA1c (NGSP) (%) 5.6  0.5 5.6  0.6 
Insulin (mU/ml)a 3.6 4.0 
Range (0.5–15.4) (0.5–69.2) 
HOMA-IRa 0.84 0.94 
Range (0.1–5.1) (0.1–15.2) 
eGFR (ml/min/1.73 m2) 74.4  16.7 73.1  14.9 
Uric acid (mg/dl) 5.1  1.4 4.8  1.9 
g-GTP (IU/l) 37.1  38.7 35.6  34.9 
ALT (IU/l) 25.1  12.7 23.9  7.4 
AST (IU/l) 20.9  13.2 20.6  10.2 
Total-c (mg/dl) 199.5  35.1 202.7  32.5
HDL-c (mg/dl) 60.1  15.8 60.3  14.1 
LDL-c (mg/dl) 118.6  33.5 120.9  28.6
Triglycerides (mg/dl)a 84.0 83.7 
Range (35–843) (25–291) 
Estradiol (pg/ml)a 16.3 14.0 
Range (10–455) (10–143) 
Testosterone (ng/ml)a 0.52 0.47 
Range (0.1–13.6) (0.1–14.3) 
Progesterone (ng/ml)a 0.18 0.18 
Range (0.03–14.9) (0.03–5.8) 
Alcohol intake % (n:yes) 49.7 (81) 42.3 (69) 
None 47.8 (78) 55.8 (91) 
Light (<23 g) 22.7 (37) 15.3 (25) 
Moderate (23–45 g) 15.9 (26) 12.9 (21) 
Heavy (46 g) 11.0 (18) 14.1 (23) 
Smoking % (n:yes) 31.9 (52) 29.4 (48) 
DM % (n:yes) 6.7 (11) 8.0 (13) 
Hypertension % (n:yes) 51.5 (84) 50.3 (82) 
Dyslipidemia % (n:yes) 33.7 (55) 35.6 (58) 
MetS % (n:yes) 23.3 (38) 29.4 (48) 
Data are means (SD), geometric mean, range, or percent.
Abbreviations: BMI, body mass index; BP, blood pressure; FPG, fasting 
resistance; eGFR, estimated glomerular filtration rate; g-GTP, g-glutam
aminotransferase; LDL, low density lipoprotein; HDL, high density lipop
The bold of p values was defined as p < 0.05.
a These variables are shown in the original scale after analysis using logvariable stratified by gender, and then we performed stepwise
regression analysis in males using significant factors shown in
univariate analysis. Finally, multiple logistic regression analysis
of fetuin-A (quartile 1 vs. quartile 4) in males was performed. We
estimated odds ratios and their 95% confidence intervals (C.I.)
per 1-unit (approximately 1 SD) increase in the variable.
Statistical significance was defined as p < 0.05. All statistical
analyses were performed using the SAS system (Release 9.3,
SAS Institute, Cary, NC).
3. Results
Plasma fetuin-A levels had a normal distribution in both males
and females (Fig. 1). Statistically significant characteristics ofs.
 Quartile 3 Quartile 4 p-Value
167 166
40.1 (67) 25.9 (43) 0.002
273.4  9.8 322.6  30.6 <0.001
65.9  10.1 63.8  9.7 0.010
23.5  3.4 24.0  3.1 0.397
83.3  10.7 83.3  9.1 0.803
 137.4  19.2 138.2  20.5 0.526
81.8  10.6 83.0  11.6 0.386
96.6  15.8 96.5  17.6 0.993
5.6  0.6 5.6  0.6 0.715
3.9 4.5 0.006
(0.8–14.8) (1.0–24.6)
0.93 1.81 0.019
(0.2–4.5) (0.2–6.9)
71.2  15.5 73.2  16.1 0.323
4.5  2.0 4.2  2.0 <0.001
31.9  35.7 34.4  32.6 0.605
23.3  6.7 26.9  7.2 0.136
20.1  11.0 24.7  18.7 0.067
 205.5  34.2 208.2  38.6 0.138
59.6  16.6 61.7  16.2 0.642
 124.8  30.9 123.4  35.1 0.312
85.5 88.5 0.679
(33–399) (36–323)
15.9 15.2 0.803
(10–422) (10–273)
0.44 0.42 0.264
(0.1–10.1) (0.1–11.1)
0.17 0.19 0.876
(0.03–10.0) (0.03–26.6)
38.9 (65) 33.1 (55) 0.010
60.4 (101) 65.7 (109) 0.021
16.8 (28) 19.3 (32)
13.8 (23) 9.6 (16)
8.4 (14) 4.2 (7)
28.1 (47) 20.5 (34) 0.123
10.8 (18) 8.4 (14) 0.612
47.3 (79) 53.6 (89) 0.708
44.9 (75) 48.8 (81) 0.103
29.3 (49) 33.7 (56) 0.013
plasma glucose; HOMA-IR, homeostasis model assessment-insulin
yl transpeptidase; ALT, alanine aminotransferase; AST, aspartate
rotein; DM, diabetes mellitus; MetS, metabolic syndrome.
 (natural)-transformed values.
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gender (inversely), age (inversely), insulin, HOMA-IR, uric acid
(inversely), alcohol intake (inversely) and the prevalence of
MetS (Table 1). Because gender was a significant factor for
fetuin-A levels, we analyzed the data stratified by gender.
Demographics of 659 subjects stratified by gender were
presented in Table 2. There was no significant difference of
fetuin-A levels between males and females. Mean  standard
deviations in fetuin-A levels were 249.7  45.1 mg/ml in males
and 262.7  55.8 mg/ml in females, respectively. In males, the
prevalence of MetS was 43.1%, and their mean HOMA-IR level
was 1.1. In females, the prevalence of MetS was 17.7%, and
their mean HOMA-IR level was 0.9. The prevalence of alcohol
intake, smoking habits and MetS in males was much higher
than in females. Tables 3a and 3b showed univariate analyses
with fetuin-A as a dependent variable stratified by gender.
Plasma fetuin-A in males (Table 3a) was associated with BMI,Table 2 – Characteristics of study subjects.
Characteristics M
Fetuin-A (mg/ml) 2
Age (years) 6
Body mass index (kg/m2) 2
Waist (cm) 8
Systolic blood pressure (mmHg) 1
Diastolic blood pressure (mmHg) 8
Fasting plasma glucose (mg/dl) 1
HbA1c (NGSP) (%) 5
Insulin (mU/ml)a 4
Range (
HOMA-IRa 1
Range (
eGFR (ml/min./1.73 m2) 7
Uric acid (mg/dl) 5
g-Glutamyl transpeptidase (IU/l) 5
Alanine aminotransferase (IU/l) 2
Aspartate aminotransferase (IU/l) 2
Total cholesterol (mg/dl) 1
HDL-cholesterol (mg/dl) 5
LDL-cholesterol (mg/dl) 1
Triglycerides (mg/dl) 1
Estradiol (pg/ml)a 2
(
Testosterone (ng/ml)a 5
(
Progesterone (ng/ml)a 0
(
Alcohol intake % (n:yes) 7
None 2
Light (<23 g) 2
Moderate (23–45 g) 2
Heavy (46 g) 1
Current smoking % (n:yes) 6
Diabetes mellitus % (n:yes) 1
Hypertension % (n:yes) 4
Dyslipidemia % (n:yes) 1
MetS % (n:yes) 4
Data are means (SD), geometric mean, range, or percent.
Abbreviations: HOMA-IR, homeostasis model assessment-insulin resist
syndrome.
a These variables are shown in the original scale after analysis using logwaist circumference, systolic and diastolic BPs, insulin,
HOMA-IR, total cholesterol, LDL-c, triglycerides and MetS.
Fetuin-A levels in females (Table 3b) were associated only with
uric acid (p < 0.01; inversely). Then, we performed multiple
stepwise regression analyses to determine independent
factors associated with fetuin-A levels in males (Table 4a).
Fetuin-A levels in males were independently associated with
MetS and LDL-c. We further investigated the associations
using multiple logistic regression analysis of fetuin-A
(quartile 1 vs. quartile 4) in males. Significant odds ratios
were found in Table 4b [(odds ratio: 1.009; 95% C.I.: 1.003–
1.015) in MetS and [(odds ratio: 1.376; 95% C.I.: 1.027–1.844) in
1-SD increment increase in LDL-c.]. The difference in fetuin-
A levels was 18.2 mg/ml between the males with (260.1 mg/ml)
and without (241.9 mg/ml) MetS. We also quantified the
13.9 mg/ml increase in fetuin-A corresponding to each
32.5 mg/dl increase in LDL-c.ales (n = 253) Females (n = 406)
49.7  45.1 262.7  55.8
6.5  9.2 65.6  10.1
4.0  3.0 23.4  3.5
4.9  8.9 81.9  10.1
36.8  18.3 136.7  19.6
3.4  11.0 80.9  10.1
03.7  21.8 92.1  11.2
.7  0.7 5.6  0.5
.3 3.8
0.5–69.2) (0.8–24.6)
.1 0.9
0.1–15.2) (0.2–6.9)
2.9  16.1 73.0  15.6
.3  2.0 4.3  1.7
0.3  47.5 25.0  20.0
6.2  11.4 23.9  17.4
5.0  15.5 19.4  18.4
90.1  36.8 208.9  33.2
4.9  15.8 62.7  14.2
16.8  32.5 126.4  32.2
13.6  82.9 86.0  35.1
3.4 20.8
10.0–64.0) (10.0–455.0)
.1 0.1
0.03–13.6) (0.03–0.8)
.3 0.4
0.03–0.8) (0.03–26.6)
4.0 (185) 21.3 (86)
5.7 (64) 78.5 (314)
6.9 (67) 13.7 (55)
7.7 (69) 4.3 (17)
8.5 (46) 4.0 (16)
4.7 (163) 4.4 (18)
0.3 (26) 4.9 (20)
5.8 (115) 37.7 (153)
8.3 (46) 24.3 (97)
3.1 (109) 17.7 (72)
ance; eGFR, estimated glomerular filtration rate; MetS, metabolic
 (natural)-transformed values.
Table 3b – Univariate analyses with fetuin-A in females.
Characteristics b p
Age (years) 0.44 0.11
Body mass index (kg/m2) 0.10 0.90
Waist (cm) 0.008 0.97
Systolic blood pressure (mmHg) 0.10 0.46
Diastolic blood pressure (mmHg) 0.16 0.55
Fasting plasma glucose (mg/dl) 0.20 0.57
HbA1c (NGSP) (%) 2.29 0.77
Insulin (mU/ml)a 9.08 0.07
HOMA-IRa 8.00 0.08
eGFR (ml/min/1.73 m2) 0.15 0.42
Uric acid (mg/dl) 4.68 0.005
g-Glutamyl transpeptidase (IU/l) 0.27 0.06
Alanine aminotransferase (IU/l) 0.19 0.24
Aspartate aminotransferase (IU/l) 0.23 0.12
Total cholesterol (mg/dl) 0.07 0.42
HDL-cholesterol (mg/dl) 0.07 0.75
LDL-cholesterol (mg/dl) 0.03 0.71
Triglycerides (mg/dl)a 10.63 0.12
Estradiol (pg/ml)a 0.004 0.95
Testosterone (ng/ml)a 5.67 0.83
Progesterone (ng/ml)a 2.25 0.13
Alcohol intake (yes) 10.73 0.12
Current smoking (yes) 3.99 0.77
Diabetes mellitus (yes) 2.97 0.81
Hypertension (yes) 4.22 0.47
Dyslipidemia (yes) 1.57 0.81
MetS (yes) 7.72 0.29
Abbreviations: HOMA-IR, homeostasis model assessment-insulin
resistance; eGFR, estimated glomerular filtration rate; MetS,
metabolic syndrome.
The bold of p value was defined as p < 0.05.
a These variables are shown in the original scale after analysis
using log (natural)-transformed values.
Table 3a – Univariate analyses with fetuin-A in males.
Characteristics b p
Age (years) 0.29 0.34
Body mass index (kg/m2) 2.62 0.005
Waist (cm) 0.81 0.01
Systolic blood pressure (mmHg) 0.32 0.04
Diastolic blood pressure (mmHg) 0.71 0.006
Fasting plasma glucose (mg/dl) 0.16 0.23
HbA1c (NGSP) (%) 3.07 0.47
Insulin (mU/ml)a 13.53 0.002
HOMA-IRa 12.05 0.002
eGFR (ml/min/1.73 m2) 0.18 0.31
Uric acid (mg/dl) 2.64 0.06
g-Glutamyl transpeptidase (IU/l) 0.03 0.64
Alanine aminotransferase (IU/l) 0.07 0.79
Aspartate aminotransferase (IU/l) 0.36 0.06
Total cholesterol (mg/dl) 0.15 0.049
HDL-cholesterol (mg/dl) 0.24 0.22
LDL-cholesterol (mg/dl) 0.24 0.01
Triglycerides (mg/dl)a 10.56 0.049
Estradiol (pg/ml)a 0.02 0.95
Testosterone (ng/ml)a 0.18 0.90
Progesterone (ng/ml)a 9.57 0.63
Alcohol intake (yes) 10.51 0.10
Current smoking (yes) 0.04 0.99
Diabetes mellitus (yes) 9.65 0.31
Hypertension (yes) 0.54 0.92
Dyslipidemia (yes) 5.18 0.48
MetS (yes) 17.68 0.002
Abbreviations: HOMA-IR, homeostasis model assessment-insulin
resistance; eGFR, estimated glomerular filtration rate; MetS,
metabolic syndrome.
The bold of p values was defined as p < 0.05.
a These variables are shown in the original scale after analysis
using log (natural)-transformed values.
Table 4a – Multiple stepwise regression analysis for the
correlates of fetuin-A in males.
Characteristics b p
MetS (yes) 17.68 0.002
LDL-cholesterol 0.20 0.02
Abbreviation: MetS, metabolic syndrome R2 = 0.176.
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In this cross-sectional cohort study in a Japanese general
population, multiple stepwise regression analysis revealed that
plasma fetuin-A level was significantly and independently
associated with MetS and LDL-c in males. The difference in
fetuin-A levels was 18.2 mg/ml between the males with (260.1 mg/
ml) and without (241.9 mg/ml) MetS. The 13.9 mg/ml increase in
fetuin-A corresponded to each 32.5 mg/dl increase in LDL-c. Our
data not only indicate statistical significance but also may
suggest clinical implication of elevated fetuin-A in atherogenesis.
4.1. Fetuin-A and MetS
Our results are consistent with previous reports from other
countries demonstrating a close association of plasma fetuin-
A level with MetS [8,12,16,25]. From Japan, only two stdies have
been reported [33,34]. In 2006, Mori et al. [33] reported for the
first time the association of fetuin-A with insulin resistance
(HOMA-IR) as well as BMI and triglycerides in a small number
of non-diabetic subjects but not in diabetic subjects, and
Ishibashi A, et al. [34], demonstrated that fetuin-A was
associated with insulin resistance in Japanese men without
apparent cardiovascular diseases. The latter did not examine
female subjects. Here, we report the association of fetuin-Awith not only insulin resistance but also MetS in a male but not
female general population.
There may be a sex-specific association of fetuin-A with
MetS [15]. Ishibashi et al. [34] reported the association of
fetuin-A with insulin resistance in men and Laughlin et al.
[27] reported the association of fetuin-A with type 2 diabetes
only in females. As apparent from Table 1, there was a
significant inverse relationship between fetuin-A levels and
the prevalence of men. Accordingly, we performed analysis
stratified by gender. A positive association of fetuin-A with
MetS was found in males, but not in females. It is considered
that men without MetS may have lower (p < 0.001) fetuin-A
levels compared to women without MetS, due to the strong
impact of BMI in all men but not in women. Thus, we
reclassified the subjects into men with and without MetS and
into women with and without MetS. Consequently, the
Table 4b – Multiple logistic regression analysis of fetuin-A (quartile 1 vs. quartile 4) in males.
Dependent variable (increment) Odds ratio 95% C.I. p
MetS (yes) 1.009 1.003–1.015 0.002
LDL-cholesterol (32.5 mg/dl)a 1.376 1.027–1.844 0.032
Abbreviation: C.I., confidence interval.
a Odds ratio per 1-increment increase in variable.
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were significantly lower (p < 0.001) than those in women
without MetS (263.9  57.3 mg/mL).
In order to investigate the underlying mechanisms for the
sex difference, we measured several sex hormones. As shown
in tables, sex hormones did not explain the sex difference. As
fetuin-A knockout mice exhibit not only insulin resistance but
also resistance to weight gain on a high fat diet, it is suggested
fetuin-A may regulate adipogenesis [5]. In fact, there have
been many reports indicating the association of fetuin-A with
BMI in humans [8,12,16,18,20,23,26,27]. However, in our study,
fetuin-A was not associated with BMI in females, probably due
to the small number of obese females (n = 113). Thus, the
negative association of fetuin-A with MetS in females may be
ascribed to the absence of obesity, i.e., MetS prevalence (43.1%
in males vs. 17.7% in females).
It may be interesting to refer reports from Asia other than
Japan where the incidence of coronary artery disease is less
than in Western countries [35]. Two reports from China [12,13]
and one report from Korea [14] indicated the association of
fetuin-A with insulin resistance and/or MetS. Thus, the
association of fetuin-A with insulin resistance and/or MetS
is rather universal and may not be influenced by genetics or
life style. From this point of view, fetuin-A may be an
interesting molecule. Previously, it was demonstrated that
fetuin-A levels were associated with not only insulin resis-
tance but also diabetes mellitus [12–14,17,18,21,22,36].
Although the number of diabetic subjects was small, we
examined whether there was a difference of fetuin-A levels
between non-diabetics and diabetics. The fetuin-A levels were
257.2  52.2 mg/ml (n = 603), and 262.1  53.4 mg/ml (n = 56) in
non-diabetics and diabetics, respectively. Thus, fetuin-A
levels were not elevated in diabetics. Our findings are
consistent with some studies [10,14,20,25,33] but not with
others [12,13,15,17–19,21–23,26,27,34]. Although we do not
know why reported values of fetuin-A in diabetics were
various, diabetes is a complicated condition in which many
inflammatory and angiogenic factors are activated [17,19,
37–40] that may influence fetuin-A levels.
Two reports [41,42] have shown that moderate alcohol
consumption decrease plasma fetuin-A. Thus, alcohol intake
is one of an important factor for fetuin-A levels. As apparent
from Table 1, our data indicated that higher alcohol
consumption was associated with lower plasma fetuin-A. It
is unknown why alcohol consumption is associated with
lower fetuin-A levels.
4.2. Fetuin-A and LDL-c
In this study, we found in males a positive association of fetuin-A
with atherogenic profile (cholesterol and triglycerides). Becausefetuin-A inhibits insulin actions, which lead to lipolysis and
efflux of free fatty acids from adipose tissue, the association of
fetuin-A with triglycerides may be understandable. Not only
multiple stepwise regression analysis revealed a significant
association of fetuin-A with LDL-c but also multiple logistic
regression analysis revealed the 13.9 mg/ml increase
in fetuin-A per each 32.5 mg/dl increase in LDL-c. The
association of fetuin-A with cholesterol was not expected,
however, a careful literature search revealed the positive
association of fetuin-A with LDL-c in several reports
[12–15,34]. Although mechanisms for the positive associa-
tion of fetuin-A with LDL-c have not been clearly elucidated,
some transcriptional factors that regulate cholesterol ho-
meostasis such as sterol regulatory element binding protein
may be involved in the regulation of hepatic synthesis of
fetuin-A [43]. Whatever the mechanism are, elevations of
fetuin-A were associated with MetS and hypercholesterol-
emia, which are strong risk factors for cerebro-cardiovascular
diseases. In fact, many clinical studies reported a high
incidence of cerebro-cardiovascular diseases in subjects
with high fetuin-A levels [23–27].
4.3. Limitations
The present study has several limitations. First, this was
a cross-sectional study and examined comparatively a
small number of subjects. Thus, nothing conclusive for the
association of fetuin-A with MetS is stated. Prospective
studies with a large number of subjects are needed to
investigate the role of fetuin-A in the development of MetS.
Second, our population was relatively healthy, and most of
them had BMI and HOMA-IR within normal limits. Moreover,
the HOMA-IR is a weak estimate of insulin resistance. Third,
since we did not have data for the prevalence of menopause
and for sex hormone-binding globulin, we were not sure
whether the sex difference for the association of fetuin-A
levels with MetS was ascribed to sex hormones. Thus, it is
necessary to investigate plasma fetuin-A levels in heteroge-
neous populations.
4.4. Conclusions
In conclusion, our data indicated that human circulating
fetuin-A was positively and independently associated with
MetS and LDL-c in males in a general population in Japan.
Plasma fetuin-A may play a role in atherosclerotic diseases.
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